Roche Holding AG
RHHBYOTCHealthcare● Active
$50.47
$-0.98(-1.90%)
Market Cap$325.1B
P/E Ratio—
52W High$60.85
52W Low$37.51
Roche Holding AG (RHHBY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RHHBY · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Jan 29, 2026EPS Actual
$1.36
Est. $1.35 · +0.7%
Revenue
$39.70B
Est. $38.96B · +1.9%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Jan 29, 2026
After Market Close
▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
RHHBY reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | $1.61 | — | — | — | $39.10B | — |
| — Q1 FY2026 | Jan 29, 2026 | $1.35 | $1.36 | +0.7% | $39.70B | $38.96B | +1.9% |
| ▲ Q3 FY2025 | Jul 24, 2025 | $1.62 | $1.74 | +7.4% | $40.06B | $15.32B | +161.4% |
| ▼ Q2 FY2025 | Jun 30, 2025 | $1.62 | $0.73 | -55.2% | $20.04B | $38.31B | -47.7% |
| ▼ Q4 FY2024 | Dec 31, 2024 | $1.17 | $0.35 | -70.4% | $33.74B | $33.84B | -0.3% |
| ◌ Q4 FY2024 | Oct 23, 2024 | — | — | — | — | — | — |
| ▼ Q2 FY2024 | Jun 29, 2024 | $1.30 | $1.09 | -16.1% | $34.33B | $32.84B | +4.5% |
| ◌ Q2 FY2024 | Apr 26, 2024 | — | — | — | — | — | — |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
$1.61
EPS Surpr.
—
Revenue
—
Q1 FY2026
Jan 29, 2026
EPS Actual
$1.36
EPS Est.
$1.35
EPS Surpr.
+0.7%
Revenue
$39.70B
Q3 FY2025
Jul 24, 2025Beat
EPS Actual
$1.74
EPS Est.
$1.62
EPS Surpr.
+7.4%
Revenue
$40.06B
Q2 FY2025
Jun 30, 2025Miss
EPS Actual
$0.73
EPS Est.
$1.62
EPS Surpr.
-55.2%
Revenue
$20.04B
Q4 FY2024
Dec 31, 2024Miss
EPS Actual
$0.35
EPS Est.
$1.17
EPS Surpr.
-70.4%
Revenue
$33.74B
Q4 FY2024
Oct 23, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Jun 29, 2024Miss
EPS Actual
$1.09
EPS Est.
$1.30
EPS Surpr.
-16.1%
Revenue
$34.33B
Q2 FY2024
Apr 26, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $1.05 | $1.06 | $1.07 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $12.3B | $12.4B | $12.5B | 2 |
| Q2 FY2026 | $15.7B | $15.8B | $15.9B | 1 |
| Q1 FY2026 | $14.1B | $14.2B | $14.2B | 2 |
| Q4 FY2025 | $14.3B | $14.4B | $14.5B | 2 |
| Q3 FY2025 | $14.9B | $14.9B | $15.0B | 3 |
| Q2 FY2025 | $14.9B | $14.9B | $15.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Jan 29, 2026 | +0.7% | $54.39 | $57.02 | +4.84% |
| ▲ Q3 FY2025 | Jul 24, 2025 | +7.4% | $41.14 | $41.42 | +0.68% |
| ▼ Q2 FY2025 | Jun 30, 2025 | -55.2% | $40.91 | $40.76 | -0.37% |
| ▼ Q4 FY2024 | Dec 31, 2024 | -70.4% | $35.16 | $34.88 | -0.80% |
| ▼ Q2 FY2024 | Jun 29, 2024 | -16.1% | $34.67 | $34.64 | -0.09% |
| ▼ Q4 FY2023 | Dec 31, 2023 | -35.1% | $36.23 | $36.35 | +0.33% |
| ▼ Q3 FY2023 | Jul 27, 2023 | -2.7% | $39.15 | $38.87 | -0.72% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -16.8% | $38.11 | $38.20 | +0.24% |
Q1 FY2026+4.84%
Report Date
Jan 29, 2026
EPS Beat/Miss
+0.7%
Price Before
$54.39
Price After
$57.02
Q3 FY2025+0.68%
Report Date
Jul 24, 2025
EPS Beat/Miss
+7.4%
Price Before
$41.14
Price After
$41.42
Q2 FY2025-0.37%
Report Date
Jun 30, 2025
EPS Beat/Miss
-55.2%
Price Before
$40.91
Price After
$40.76
Q4 FY2024-0.80%
Report Date
Dec 31, 2024
EPS Beat/Miss
-70.4%
Price Before
$35.16
Price After
$34.88
Q2 FY2024-0.09%
Report Date
Jun 29, 2024
EPS Beat/Miss
-16.1%
Price Before
$34.67
Price After
$34.64
Q4 FY2023+0.33%
Report Date
Dec 31, 2023
EPS Beat/Miss
-35.1%
Price Before
$36.23
Price After
$36.35
Q3 FY2023-0.72%
Report Date
Jul 27, 2023
EPS Beat/Miss
-2.7%
Price Before
$39.15
Price After
$38.87
Q2 FY2023+0.24%
Report Date
Jun 30, 2023
EPS Beat/Miss
-16.8%
Price Before
$38.11
Price After
$38.20
Avg Beat Reaction+2.76%
Avg Miss Reaction-0.23%
Beat Rate2 / 8 quarters
Largest Move+4.84% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RHHBY ends December
Roche Holding AG (RHHBY) most recently reported earnings on January 29, 2026 for Q1 FY2026, posting EPS of $1.36 (in line with the analyst consensus of $1.35). RHHBY has beaten EPS estimates for 2 consecutive quarters. The next RHHBY earnings date is expected around September 1, 2026.
Each quarter, investors track RHHBY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RHHBY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RHHBY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RHHBY earnings · 4 questionsRoche Holding AG's next earnings report is expected around September 1, 2026. RHHBY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RHHBY historically reports after market close (AMC).
RHHBY earnings datewhen is RHHBY earningsRHHBY next earnings datewhen does RHHBY report earningsRHHBY earnings calendar
▸ Source: FMP · Roche Holding AG SEC filings · US GAAP · Roche Holding AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026